(Finance) – The European Medicines Agency (EMA) has given conditional authorization toplacing Paxlovid on the market, the oral drug manufactured by Pfizer for the Covid-19 cure.
The medicine is recommended for the treatment of coronavirus in adults who do not need oxygen but they are high-risk aggravation. The studies presented – explains the EMA – confirm that the treatment has “significantly” reduced hospitalizations and deaths in patients who have at least one underlying condition that puts them at risk of severe Covid.
Paxlovid is the first oral antiviral medicine recommended in the EU and contains two active substances, PF-07321332 and ritonavir, in two different tablets. The first works by reducing the ability of the SARS-CoV-2 virus to multiply in the body while ritonavir prolongs the action of the other principle, allowing it to stay longer in the body. Side effects were generally mild.
There most of the patients enrolled in the study she had been infected with the Delta variant, but the pill is also expected to be effective against Omicron and other variants.